However, genetic testing can identify carriers of variants in complement genes that could be amendable for new (targeted) treatments that are currently in development for AMD (e.g. CFI gene therapy and FH supplementation), and genetic testing can avoid misdiagnosis of inherited macular dystrophies (de Breuk et al., 2021a). The gene discussed is CFI; the disease is Macular dystrophy.